This week, the Journal of Clinical Investigation published a study that addresses cerebral malaria, an illness that affects one percent of the 216 million people diagnosed with malaria globally each year. Led by neuroscientist Ana Rodriguez, Ph.D., the study was partially funded by a three-year grant from the Dana Foundation in 2009, as part of the now discontinued Neuroimmunology program.
Rodriguez and her team at NYU Langone Medical Center found that by combining the standard treatment of malaria (a drug called chloroquine) with two different types of drugs used to treat hypertension, the survival rate of infected mice more than tripled.
In an article highlighting the study, Rodriguez says:
About one in five patients with cerebral malaria die within 48 hours of being admitted to the hospital, and the time it takes for the parasite-killing drug to take effect…If we could add a drug that stopped hemorrhages during that window, it would buy time and save lives.
To read the press release detailing this study, click here.
– Seimi Rurup